Oslo, Norway, November 18, 2025 - Lytix Biopharma AS ("Lytix" or the "Company")
today releases its results for the third quarter of 2025.

Post-quarter-end brought a surge of positive news for Lytix's first asset,
ruxotemitide (formerly LTX-315), with two key clinical results in both
neoadjuvant melanoma and basal cell carcinoma (BCC). These findings, outlined
below, have prompted the company to accelerate its development plan, focusing on
the fastest route to bring the groundbreaking drug to patients.

Q3 2025 highlights and developments
o	Licensing partner Verrica Pharmaceuticals previously announced strong clinical
results from their Phase II study with ruxotemitide, including a 97% calculated
objective response rate and a 51% complete histologic clearance rate
o	New data from the ongoing Phase II study was announced on November 10, 2025,
at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting in
National Harbor, which included:
o	Histologic assessment in non-injected lesions suggests a potential
abscopal-like effect
o	A strong increase in the density of CD4+, CD8+ T-cells and B cells, all of
which support a local anti-tumor response within the tumors
o	On November 14, 2024, Verrica announced that the FDA confirmed alignment with
their plan for the Phase 3 program to include two placebo-controlled studies,
each involving approximately 100 subjects, with a primary endpoint of complete
clearance assessed at week 14. Based on discussions with the FDA, Verrica
expects these studies will be sufficient to support a New Drug Application (NDA)
filing, with long-term follow-up studies to be conducted as post-approval
commitments
o	On November 11, 2025, Dr. Henrik Jespersen's team presented an interim update
at the Nordic Melanoma Meeting on the Phase II NeoLIPA study
o	44% pathological complete response (pCR) and 55% major pathological response
(MPR) among the first nine evaluable patients
o	Overall pathological response seen in 88% of patients, with a favorable safety
profile
o	No relapses reported to date
o	Lytix is in the final stages of developing LTX-401, a proprietary asset, and
is currently evaluating clinical development strategies to determine the best
timing and approach for advancing into clinical trials
o	Cash and short-term financial investments amounted to NOK 90 million as of
September 30, 2025
o	A non-cash share option expense of NOK 11.9 million related to the new option
program launched in September temporarily increases the reported net loss

Ruxotemitide is advancing commercialization through two strategic avenues: our
internal work on neoadjuvant melanoma via the NeoLIPA study and a close
partnership with Verrica Pharmaceuticals for the non-surgical treatment of basal
cell carcinoma. These dual initiatives offer near- and mid-term opportunities to
create significant market value in superficial tumors. 

At the same time, Lytix is expanding into deep-seated tumors with LTX-401.
Backed by strong pre-clinical data and positive regulatory feedback, we are
developing a strategic plan for this asset. 

While Lytix is progressing ruxotemitide toward market approval, the company
remains open to valuable partnerships that can speed up development, maximize
the global potential of the program, and ensure patients gain access to this
drug as quickly as possible. With a focused pipeline and disciplined financial
management, Lytix is well-positioned for 2026.

Webcast details:
The results will be presented in a webcast with CEO Øystein Rekdal and CFO Gjest
Breistein today.

Date: Tuesday, November 18th, 2025
Time: 10:00 AM CEST

Questions may be submitted in advance to: post@lytixbiopharma.com

The presentation and Q&A session will be conducted in English. You can view the
live event by registering here:
https://channel.royalcast.com/landingpage/hegnarmedia/20251118_1/ 

A recording will be available after the event at:
https://www.lytixbiopharma.com/financial-reports 

For more information, please contact: 
Gjest Breistein, CFO 
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma's lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to maintaining durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as mono- and combination therapy. Lytix
is listed on Euronext Growth Oslo under the ticker LYTIX.
For more information, visit www.lytixbiopharma.com